Vitamin K

Summary

Vitamin K (CHEMBL1201519) is an approved unknown; indicated across 14 conditions including atrial fibrillation and relapsing-remitting multiple sclerosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 14 conditions
• Clinical trials: 29

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201519
Name	Vitamin K
Type	Unknown
Max phase	4

Also known as: Vitamin k, Vitamin K, VITAMIN K

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

14 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atrial fibrillation	3	MONDO:0004981	EFO:0000275
relapsing-remitting multiple sclerosis	3	MONDO:0005314	EFO:0003929
thrombotic disease	2	MONDO:0000831	MONDO:0000831
Crohn disease	1	MONDO:0005011	EFO:0000384
neoplasm	1	MONDO:0005070	EFO:0000616
rheumatoid arthritis	1	MONDO:0008383	EFO:0000685
ulcerative colitis	1	MONDO:0005101	EFO:0000729
Alzheimer disease	1	MONDO:0004975	MONDO:0004975
prostate adenocarcinoma	1	MONDO:0005082	EFO:0000673
psoriasis	1	MONDO:0005083	EFO:0000676
melanoma	1	MONDO:0005105	EFO:0000756
atopic eczema	0	MONDO:0004980	EFO:0000274

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 29.

Phase distribution

Phase	Trials
Not specified	14
PHASE1	8
PHASE4	4
PHASE3	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06881628	PHASE4	RECRUITING	Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients
NCT07515664	PHASE4	RECRUITING	Vitamin K for Perioperative Warfarin Management
NCT03941535	PHASE4	UNKNOWN	Comparison of Vitamin K Doses in Patients With Larger Burn Injuries
NCT05742295	PHASE4	COMPLETED	Prevention of Cefoperazone-induced Coagulopathy
NCT00183001	PHASE3	COMPLETED	Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
NCT01462318	PHASE3	COMPLETED	An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
NCT01400646	PHASE1	COMPLETED	A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers
NCT01517399	PHASE1	COMPLETED	Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
NCT01636557	PHASE1	COMPLETED	A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis
NCT02182336	PHASE1	COMPLETED	Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers
NCT02243553	PHASE1	COMPLETED	Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers
NCT02740712	PHASE1	COMPLETED	Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
NCT03363815	PHASE1	COMPLETED	A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects
NCT04246762	PHASE1	COMPLETED	Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
NCT05891119	EARLY_PHASE1	COMPLETED	Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
NCT05505552	Not specified	ACTIVE_NOT_RECRUITING	Effects of Vitamin K on Lower-extremity Function in Adults With Osteoarthritis:
NCT06855953	Not specified	NOT_YET_RECRUITING	Vitamin K and Cognition in Coronary Heart Disease (NutriCog)
NCT07041645	Not specified	NOT_YET_RECRUITING	Bioavailability of Different Vitamin K Vitamers Studied Using 13C-labelled Vitamin K Vitamers
NCT07256769	Not specified	RECRUITING	Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis
NCT00287313	Not specified	COMPLETED	Daily Vitamin K in Patients on Warfarin With Unstable INRs
NCT00336232	Not specified	COMPLETED	Determinants of Vitamin K Metabolism
NCT00363038	Not specified	COMPLETED	Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising
NCT00826254	Not specified	UNKNOWN	Nutritional Problems After Lung and Heart Transplantation
NCT01034124	Not specified	COMPLETED	Mechanisms Underlying Drug-Diet Interactions
NCT01143831	Not specified	COMPLETED	Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation
NCT01910142	Not specified	COMPLETED	Effect of Nutrition on Bone Metabolism as Assessed by 41Ca
NCT02278692	Not specified	COMPLETED	Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
NCT04285450	Not specified	COMPLETED	The Clinical Effect of Vitamin K Administration in Type 2 Diabetic Patients
NCT04984083	Not specified	COMPLETED	Maternal and Neonatal Benefits of Prophylactic Administration of Vitamin K Before Elective Cesarean Section

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).